Physician profile
Gail E Correale
NPI 1619038841
$3,891.10
in general payments reported to CMS, 2019-2025
23 companies · $806 in 2025
The $806 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $155 · 2021: $524 · 2022: $742 · 2023: $487 · 2024: $754 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,047.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $399.42 | 2021-2025 | Precision7, Precision 1 |
| Tarsus Pharmaceuticals, INC. | $396.83 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $332.23 | 2023-2025 | Cequa |
| Glaukos Corporation | $288.32 | 2021-2022 | |
| Dompe US, INC. | $247.18 | 2024-2025 | Oxervate |
| Coopervision INC. | $232.34 | 2019-2022 | |
| Sight Sciences, INC. | $226.32 | 2019-2023 | Tearcare System |
| Amgen INC. | $205.80 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $194.84 | 2023-2024 | |
| Johnson & Johnson Vision Care, INC. | $181.09 | 2021-2025 | Acuvue |
| Lumenis Be INC | $148.51 | 2022 | |
| Bausch & Lomb Americas INC. | $144.72 | 2023-2024 | Vyzulta, Infuse |
| Genzyme Corporation | $133.03 | 2020-2022 | |
| Spark Therapeutics, INC. | $123.39 | 2019 | |
| Abbvie INC. | $102.66 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $100.07 | 2023 | Soliris |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.31 | 2019 | |
| Oyster Point Pharma, INC. | $81.68 | 2022-2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $66.37 | 2021 | |
| Asd Specialty Healthcare, LLC | $62.15 | 2020 | |
| Maculogix, INC. | $58.26 | 2019 | |
| Allergan, INC. | $50.16 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gail Correale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.